JohnREckardtMD

PubMed

• 110 citations
  Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin As Treatment for Chemotherapy-Naive Patients With Ex...
  John R. Eckardt, Joachim von Pawel, Z. Papai, A. Tomova, Valentina Tzekova, T. Crofts, Sarah Brannon, Paul Wissel, Graham Ross> ;Journal of Clinical Oncology. 2006 May 1
• 48 citations
  Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)
  Amanda F. Cashen, Mark B. Juckett, Alcee Jumonville, Mark R. Litzow, Patrick J. Flynn, John R. Eckardt, Betsy LaPlant, Kristina Laumann, Charles Erlichman, John F. DiP...> ;Annals of Hematology. 2012 Jan 1
• Impact of direct physician-to-physician contact on accelerating oncology clinical trial accrual in multiple tumor types.
  Eckardt JR, DeMaggio AW, Peracha O, Nemeth A, Sarvepalli S, Levonyak M, Ku N> ;J. Clin. Oncol.. 2011-05-20
• Clinical trial site engagement and commitment through direct physician interaction with investigators.
  Ku N, DeMaggio AW, Maan-Gupte M, Rowley L, Sarvepalli S, Levonyak M, Eckardt JR> ;J. Clin. Oncol.. 2011-05-20
• 9 citations
  Safety and resource utilization by non-small cell lung cancer histology: results from the randomized phase III study of pemetrexed plus cisplatin versus gemcitabine pl...
  Silvia Novello, Francisco Luís Pimentel, Jean-Yves Douillard, Mary O'Brien, Joachim von Pawel, John R. Eckardt, Astra M. Liepa, Lorinda Simms, Carla Visseren-Grul, Lui...> ;Journal of Thoracic Oncology. 2010 Oct 1
• 29 citations
  A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: A phase 2 consortium study
  Gary A. Croghan, Vera J. Suman, William J. Maples, Mark R. Albertini, Gerald P. Linette, Lawrence E. Flaherty, John R. Eckardt, Cynthia X. Ma, Svetomir N. Markovic, Ch...> ;Cancer. 2010 Jul 15
• 20 citations
  A Phase I Study of 7-t-Butyldimethylsilyl-10-Hydroxycamptothecin in Adult Patients with Refractory or Metastatic Solid Malignancies
  Susanne M. Arnold, John Rinehart, Eleftheria Tsakalozou, John R. Eckardt, Scott Z. Fields, Brent J. Shelton, Philip A. DeSimone, Bryan K. Kee, Jeffrey A. Moscow, Marko...> ;Clinical Cancer Research. 2010 Jan 15
• Long-term follow-up (>20 years) for one of the original randomized prospective trials evaluating adjuvant chemotherapy in patients with high-grade operable osteosarcoma.
  Tap WD, Eilber FR, Rosen G, Eckardt J, Schwartz A, Federman N, Eilber FC> ;J. Clin. Oncol.. 2009-05-20
• Pharmacokinetics (PK) of the highly lipophilic and blood stable camptothecin AR-67 (7-t-butyldimethylsilyl-10- hydroxycamptothecin) in adult patients with solid malign...
  Leggas M, Horn J, Tsakalozou E, Moscow JA, Fields SZ, Houchins JC, Eckardt JR, DeSimone P, Kee BK, Rinehart JJ, Arnold SM> ;J. Clin. Oncol.. 2009-05-20
• Clinical and pharmacokinetic (PK) findings in a phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) in patients with refractory solid tumors.
  Arnold SM, Horn J, Eckardt JR, Rinehart JJ, DeSimone P, Fields SZ, Kee BK, Moscow JA, Houchins JC, Leggas M> ;J. Clin. Oncol.. 2009-05-20
• Impact of direct physician-to-physician contact on accelerating oncology clinical trial accrual.
  Eckardt JR, Ku N, DeMaggio A, Reese M, Levonyak M, Jain V> ;J. Clin. Oncol.. 2009-05-20
• 71 citations
  Phase II Study of Picoplatin As Second-Line Therapy for Patients With Small-Cell Lung Cancer
  John R. Eckardt, Dimitri L. Bentsion, Oleg Lipatov, Igor S. Polyakov, Frederick R. MacKintosh, David A. Karlin, G. S. Baker, H. B. Breitz> ;Journal of Clinical Oncology. 2009 Apr 20
• Efficacy of PS-341 in combination with paclitaxel (PAC) and carboplatin (CBDCA) for the treatment of metastatic melanoma (MM): A phase II consortium study.
  Maples WJ, Suman V, Croghan GA, Albertini MR, Linette G, Flaherty LE, Eckardt J, Amatruda T, Erlichman CE> ;J. Clin. Oncol.. 2008-05-20
• 33 citations
  Recent advances with topotecan in the treatment of lung cancer
  Mary O'Brien, John R. Eckardt, Rodryg Ramlau> ;The Oncologist. 2007 Oct 1
• 238 citations
  Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
  John R. Eckardt, Joachim von Pawel, Jean-Louis Pujol, Z. Papai, Elisabeth Quoix, Andrea Ardizzoni, Ruth Poulin, A. Preston, Graham Dane, Graham Ross> ;Journal of Clinical Oncology. 2007 May 20
• Compliance with oral topotecan in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
  Eckardt JR, Ramlau R, Gervais R, Shepherd F, O'Brien M, Ciuleanu T, Dharan B, Wissel P, Ross G> ;J. Clin. Oncol.. 2006-06-20
• Comparable activity with oral topotecan/cisplatin (TC) and IV etoposide/cisplatin (PE) as treatment for chemotherapy-naïve patients (pts) with extensive disease small ...
  Eckardt JR, von Pawel J, Manikhas G, Papai Z, Tomova A, Tzekova V, Crofts T, Brannon S, Wissel P, Ross G> ;J. Clin. Oncol.. 2005-06-01
• 23 citations
  Emerging Role of Weekly Topotecan in Recurrent Small Cell Lung Cancer
  John R. Eckardt> ;The Oncologist. 2004 Dec 1
• Early results of a phase I study of weekly topotecan (T) in combination with weekly platinum compounds.
  White LA, Sjak-Shie NN, Kimminau C, Schmidt AM, Greco AO, Eckardt JR> ;J. Clin. Oncol.. 2004-07-15
• Skin rash and good performance status (PS) predict improved survival with gefitinib for patients with advanced non-small cell lung cancer (NSCLC).
  Mohamed MK, Ramalingam S, Lin Y, Gooding WE, Cronin W, Eckardt JR, Belani CP> ;J. Clin. Oncol.. 2004-07-15
• A randomized phase III trial (389): Oral topotecan/cisplatin (TC) vs IV etoposide/cisplatin (PE) as treatment for chemotherapy-naïve patients (pts) with extensive dise...
  Eckardt JR, Von Pawel J, Manikhas G, Papai Z, Tomova A, Tzekova V, Crofts T, Poulin R, Levin J, Ross G> ;J. Clin. Oncol.. 2004-07-15
• A preliminary retrospective analysis of weekly topotecan in recurrent small-cell lung cancer.
  Kasturi VK, Eckardt JR, Greco FA> ;J. Clin. Oncol.. 2004-07-15
• Phase II study of synthadotin (SYN-D; ILX651) administered daily for 5 consecutive days once every 3 weeks (qdx5q3w) in patients (Pts) with inoperable locally advanced...
  Ebbinghaus S, Hersh E, Cunningham CC, O'Day S, McDermott D, Stephenson J, Richards DA, Eckardt J, Haider OL, Hammond LA> ;J. Clin. Oncol.. 2004-07-15
• 26 citations
  A Randomized Phase I and Pharmacological Trial of Sequences of 1,3-bis(2-Chloroethyl)-1-Nitrosourea and Temozolomide in Patients with Advanced Solid Neoplasms
  Lisa A. Hammond, John R. Eckardt, John G. Kuhn, Stanton L. Gerson, Thomas R. Johnson, Lon Smith, Ronald Drengler, Elizabeth Campbell, Geoffrey R. Weiss, Daniel D. Von ...> ;Clinical Cancer Research. 2004 Mar 1
• 15 citations
  Development of docetaxel in advanced non-small-cell lung cancer.
  Chandra P. Belani, J R Eckardt> ;Lung Cancer. 2004 Jan 1
• Join now to see all